BSEBeryl Drugs LtdMediumPositive
Announced Wed, 11 Mar · 14:17 IST

DISCLOSURE UNDER REGULATION 7(2) OF PROHIBITION OF INSIDER TRADING

Promoter Stake BuyOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Beryl Drugs Ltd has submitted a disclosure to BSE under Regulation 7(2) of SEBI's Prohibition of Insider Trading Regulations, 2015. The disclosure was made by Sudhir Sethi, the main Promoter and Director of the company (DIN: 00090172), informing about his acquisition of 11,786 shares, which represents 0.23% of the company's equity. The filing is a regulatory requirement to report insider trading-related share transactions by promoters.

Likely market impact

This is a small promoter buy (0.23%) and is largely a routine compliance filing. It signals modest insider confidence but is too small in size to materially affect the stock price or shareholder value.